ArticlePloS one2026
Referral patterns in the CKD.QLD Registry: A call for revisiting the definition of late referral.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTimely nephrology referral is considered important in chronic kidney disease (CKD), however, definitions of "late referral" vary, and may not accurately reflect patient risk or predict outcomes. STUDY
aimTo evaluate referral patterns among Chronic Kidney Disease Queensland Registry (CKD.QLD) participants, focusing on the timing and appropriateness of referrals and their association with clinical outcomes.
methodsWe conducted a retrospective cohort study of adults (≥18 years) in the CKD.QLD Registry from seven public nephrology clinics (May 2011-June 2018). Participants were followed from referral to kidney replacement therapy (KRT), death, or study end. Late referral was defined as initiation of KRT within 12 months of referral among those who progressed to KRT. Comorbidity burden was assessed using an unweighted count. A primary Cox proportional hazards model was performed in KRT starters. To address selection bias, a multivariable Fine-Gray competing risks model with left truncation was applied to the full cohort, incorporating pre-KRT mortality.
resultsAmong 3,775 participants, 775 (20.5%) developed end-stage kidney disease and 513 of these (66.2%) initiated KRT. Overall, 722 (19.1%) died, including 598 before KRT. Late referral occurred in 60 (11.7%) KRT patients. In a fully adjusted Cox proportional hazards model restricted to the 513 participants who progressed to KRT, late referral was not associated with post-KRT mortality (hazard ratio [HR] 0.91; 95% CI 0.52-1.59; p = 0.74). On the other hand, in a fully adjusted Fine-Gray model, longer pre-KRT care showed a statistically significant but clinically small increase in post-KRT mortality (sub-distribution hazard ratio [SHR]1.004 per additional month; 95% CI 1.001-1.006; p = 0.004). This minimal effect was supported by near-overlapping cumulative incidence curves across 1-, 3-, 6-, and 12-month referral thresholds. In contrast, baseline clinical factors were strongly associated with post-KRT mortality: higher comorbidity score (SHR 2.113; 95% CI 1.792-2.493; p < 0.001), pre-existing cardiovascular disease (SHR 1.910; 95% CI 1.232-2.961; p = 0.004), and Indigenous status (SHR 1.931; 95% CI 1.193-3.127; p = 0.007).
conclusionAfter accounting for pre-dialysis deaths, longer pre-KRT care had minimal impact on post-dialysis survival. Outcomes were instead driven mainly by baseline comorbidity and cardiovascular disease rather than referral timing. These findings support a shift from primarily using time-based referral criteria toward risk-stratified approaches in CKD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.